Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Multi-component nutritional supplement improves markers of vascular health (opens in a new tab)

news-medical.net · 2026-11-04

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of four claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 2 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredBlood vessel function improved within one hour of the first dose.View evidenceHide evidence

As statedwithin one hour

Why this verdict

The abstract-level profile only states that an acute post-dose vascular assessment was performed. It does not report acute outcome data, an effect estimate, which vascular measure improved, or a one-hour timing after the first dose. Therefore the specific claim that blood vessel function improved within one hour is not verifiable from the abstract-depth evidence.

1

Study evidence

An acute post-dose vascular assessment was included in the trial visit procedures, but the abstract does not present any acute (post-dose) outcome data.

“Vascular assessments were performed at baseline and after 6 months (with an acute post-dose assessment).”
Claim 2 of 4Not coveredThe study measured cardiovascular health biomarkers rather than clinical outcomes, and the authors said larger studies are needed to determine whether the changes translate into longer-term health benefits.View evidenceHide evidence

Why this verdict

The supplied profile supports that the study measured vascular and cardiometabolic biomarkers or surrogates such as FMD, PWV, blood pressure, lipids, and SCORE2/SCORE2-OP rather than clinical cardiovascular events. However, the abstract-depth profile does not include the quoted author statement that the study was not designed to assess clinical outcomes, nor the stated call for larger studies to determine long-term health benefits. The claim is therefore only partly supported and not fully verifiable at this evidence depth.

1

Study evidence

Compared with control, the supplement improved endothelial function at 6 months as measured by brachial artery FMD.+2.9% (95% CI 2.1–3.8)

“The effects of a supplement to target ageing mechanisms on vascular function study was a double-blind, randomized, controlled trial.”
2

Study evidence

The supplement reduced arterial stiffness relative to control as measured by pulse wave velocity (ΔΔPWV −1.18 m/s; 95% CI −2.00 to −0.36).−1.18 m/s (95% CI −2.00 to −0.36)

“Secondary outcomes included pulse wave velocity (PWV), peripheral and central blood pressure, augmentation index, lipid profile, and estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP).”
Claim 3 of 4SupportedA multi-component nutritional supplement has been found to improve markers of vascular health in a randomized controlled trial led by the University of Surrey.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that a randomized, double-blind controlled trial of a multi-ingredient nutritional powder versus control found improvements in vascular health markers over 6 months, including FMD as the primary endothelial-function outcome and secondary PWV and systolic blood pressure outcomes. The University of Surrey leadership detail is not contained in the supplied paper profile, but the scientific finding as framed is supported.

1

Study evidence

Compared with control, the supplement improved endothelial function at 6 months as measured by brachial artery FMD.+2.9% (95% CI 2.1–3.8)

“The effects of a supplement to target ageing mechanisms on vascular function study was a double-blind, randomized, controlled trial.”
2

Study evidence

The supplement reduced arterial stiffness relative to control as measured by pulse wave velocity (ΔΔPWV −1.18 m/s; 95% CI −2.00 to −0.36).−1.18 m/s (95% CI −2.00 to −0.36)

“Secondary outcomes included pulse wave velocity (PWV), peripheral and central blood pressure, augmentation index, lipid profile, and estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP).”
Claim 4 of 4SupportedAfter six months, participants receiving the supplement, known as NOVOS Core, showed improvements in endothelial function, arterial stiffness and systolic blood pressure compared with those who did not receive the supplement.View evidenceHide evidence

Why this verdict

The paper profile reports 6-month between-group improvements favoring the supplement for endothelial function/FMD (+2.9%), arterial stiffness/PWV (-1.18 m/s), and peripheral systolic blood pressure (-6.1 mmHg). These were measured in a randomized controlled design, so the causal framing for measured biomarkers is supported at abstract depth. The product name NOVOS Core is not independently verified in the supplied profile.

1

Study evidence

Compared with control, the supplement improved endothelial function at 6 months as measured by brachial artery FMD.+2.9% (95% CI 2.1–3.8)

“The effects of a supplement to target ageing mechanisms on vascular function study was a double-blind, randomized, controlled trial.”
2

Study evidence

The supplement reduced arterial stiffness relative to control as measured by pulse wave velocity (ΔΔPWV −1.18 m/s; 95% CI −2.00 to −0.36).−1.18 m/s (95% CI −2.00 to −0.36)

“Secondary outcomes included pulse wave velocity (PWV), peripheral and central blood pressure, augmentation index, lipid profile, and estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract mentions an acute post-dose assessment but does not report acute post-dose results, one-hour timing, or immediate effect estimates.

    The story instead asserts that blood vessel function improved within one hour of the first dose, which outruns the abstract-level evidence supplied in the paper profile.

    From Acute post-dose assessment within RCT visits

  • The trial had a moderate sample size and incomplete follow-up: 61 randomized participants and 43 completing both visits.

    This limitation is listed in the paper profile but is not included among the story caveats.

    From Double-blind randomized controlled trial (parallel-group); Double-blind randomized controlled trial (parallel-group); se

  • Participants were apparently healthy adults with low baseline estimated cardiovascular risk, limiting generalizability to higher-risk or clinical populations.

    The story mentions the biomarker-versus-clinical-outcome caveat but does not report the apparently healthy, low-risk study population or the resulting generalizability limitation.

    From Double-blind randomized controlled trial (parallel-group)

  • Arterial stiffness, blood pressure, lipids, and SCORE2/SCORE2-OP were secondary outcomes rather than the prespecified primary endpoint.

    The story presents the secondary vascular markers alongside endothelial function but does not distinguish the primary FMD endpoint from the secondary outcomes, which affects interpretation of the breadth of the findings.

    From Double-blind randomized controlled trial (parallel-group); secondary outcomes reported at 6 months

4 things the story did carry across
  • The main trial was a randomized, double-blind, controlled 6-month human intervention comparing a multi-ingredient nutritional powder with control.
  • Primary 6-month endpoint: endothelial function measured by brachial artery flow-mediated dilation improved versus control, with ΔΔFMD +2.9% (95% CI 2.1 to 3.8).
  • Secondary 6-month outcomes included reduced arterial stiffness/PWV and lower peripheral systolic blood pressure; lipids were unchanged.
  • The study assessed vascular biomarkers and risk surrogates rather than clinical cardiovascular outcomes.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether 6 months of a multi-ingredient nutritional powder improves endothelial function in apparently healthy adults vs control (primary outcome: brachial artery flow-mediated dilation, FMD).Double-blind randomized controlled trial (parallel-group)Expand

In plain English

In a double-blind, randomized, controlled trial in apparently healthy adults, daily intake of a multi-ingredient nutritional powder for 6 months improved endothelial function as measured by brachial artery flow-mediated dilation (FMD): between-group change in FMD (ΔΔFMD) at 6 months was +2.9% (95% CI 2.1–3.8) favoring the supplement.

Key findings

  • Compared with control, the supplement improved endothelial function at 6 months as measured by brachial artery FMD.+2.9% (95% CI 2.1–3.8)
“The effects of a supplement to target ageing mechanisms on vascular function study was a double-blind, randomized, controlled trial.”
What this piece can’t prove
  • Study population described as apparently healthy adults with low baseline estimated cardiovascular risk, limiting generalizability.

1 further detail could not be confirmed from the summary.

2human in vivoAssess longer-term effects of the supplement on other vascular ageing markers and cardiometabolic risk surrogates (PWV, blood pressure/central hemodynamics, lipids, SCORE2/SCORE2-OP) over 6 months.Double-blind randomized controlled trial (parallel-group); secondary outcomes reported at 6 monthsExpand

In plain English

Abstract of a double-blind randomized controlled trial (6 months) reports between-group changes for secondary vascular ageing outcomes and cardiometabolic risk surrogates: the supplement reduced arterial stiffness (PWV), lowered peripheral systolic blood pressure, and produced a small reduction in estimated 10‑year cardiovascular risk (SCORE2/SCORE2‑OP); lipid measures were reported as unchanged. Results are presented as ΔΔ (between-group differences in change) with 95% CIs; 61 participants were randomized and 43 completed both visits.

Key findings

  • The supplement reduced arterial stiffness relative to control as measured by pulse wave velocity (ΔΔPWV −1.18 m/s; 95% CI −2.00 to −0.36).−1.18 m/s (95% CI −2.00 to −0.36)
  • The supplement lowered peripheral systolic blood pressure versus control (ΔΔSBP −6.1 mmHg; 95% CI −10.9 to −1.3).−6.1 mmHg (95% CI −10.9 to −1.3)
“Secondary outcomes included pulse wave velocity (PWV), peripheral and central blood pressure, augmentation index, lipid profile, and estimated 10-year cardiovascular risk (SCORE2/SCORE2-OP).”
What this piece can’t prove
  • Secondary outcomes reported with a modest randomized sample (61 randomized; 43 completers), with attrition between randomization and follow-up.

2 further details could not be confirmed from the summary.

3human in vivoAssess acute (post-dose) vascular effects of the supplement during the assessment visits (acute post-dose assessment).Acute post-dose assessment within RCT visitsExpand

In plain English

The randomized, double-blind controlled trial included an acute post-dose vascular assessment at the trial visits (baseline and 6 months). The abstract states this assessment was performed but does not report any acute (post-dose) outcome data or numerical results for immediate vascular effects.

Key findings

  • An acute post-dose vascular assessment was included in the trial visit procedures, but the abstract does not present any acute (post-dose) outcome data.
“Vascular assessments were performed at baseline and after 6 months (with an acute post-dose assessment).”
What this piece can’t prove
  • Limited and partially complete sample (61 randomized; 43 completers) reduces certainty about the representativeness and power for acute effect analyses.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

ARTERIAL STIFFNESS AS A PREDICTOR OF OUTCOMES IN THE SYSTOLIC BLOOD PRESSURE INTERVENTION TRIAL

Innovation in Aging · 2017 · Crossref

Source (opens in a new tab)
Candidate

Pulsatile Stress, Arterial Stiffness, and Endothelial Function

Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases · 2014 · Crossref

Source (opens in a new tab)
Candidate

Tadalafil: effects on blood pressure and arterial stiffness in systolic hypertension

Http://isrctn.org/> · 2012 · Crossref

Source (opens in a new tab)
Candidate

1. ACUTE INFLAMMATION INCREASES ARTERIAL STIFFNESS, CENTRAL SYSTOLIC BLOOD PRESSURE, AND ENDOTHELIAL DYSFUNCTION IN HEALTHY SUBJECTS

Artery Research · 2009 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.